Effect of treatment in loss of retinal nerve fibre layer in multiple sclerosis patients;Influencia del tratamiento en la pérdida de fibras nerviosas de la retina en pacientes con esclerosis múltiple

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 85, Issue 6, 2010, Pages 209-214

  Garcia Martin E ^a   Pueyo, V ^a   Fernandez J ^a   Martin J ^a   Ara, J R ^a   Almarcegui, C ^a   Dolz, I ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Interferon; Multiple sclerosis; Optical coherence tomography; Retinal nerve fibre layer; Scanning laser polarimetry; Visual evoked potentials

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATHOLOGY; RETINA; RETINA DISEASE;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETINA; RETINAL DISEASES; YOUNG ADULT;

EID: 78549262669     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oftal.2010.08.004     Document Type: Article

References (33)

1. IFNB Multiple Sclerosis Study Group Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology. 57 2001 S3 9
2. The IFNB Multiple Sclerosis Study Group, The University of British Columbia, MS/MRI., Analysis Group Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial Neurology. 45 1995 1277 1285
3. D.W. Paty, D.K. Li UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology. 43 1993 662 667
4. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352: 1491-7.
5. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology. 1999;53:679-86.
6. D.K. Li, and D.W. Paty Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis Ann Neurol. 46 1999 197 206
7. L.D. Jacobs, D.L. Cookfair, R.A. Rudick, R.M. Herndon, J.R. Richert, and A.M. Salazar A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG) Mult Scler. 1 1995 118 135
8. K.P. Johnson, B.R. Brooks, C.C. Ford, A. Goodman, J. Guarnaccia, and R.P. Lisak Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group 1 Mult Scler. 6 2000 255 266
9. G. Comi, M. Filippi, and J.S. Wolinsky European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group 2 Ann Neurol. 49 2001 290 297
10. J. Palace Inflammation versus neurodegeneration: consequences for treatment J Neurol Sci. 259 2007 46 49
11. S.L. Hauser, and J.R. Oksenberg The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration Neuron. 52 2006 61 76
12. J.B. Fisher, D.A. Jacobs, C.E. Markowitz, S.L. Galetta, N.J. Volpe, and M.L. Nano-Schiavi Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis Ophthalmology. 113 2006 324 332
13. V. Pueyo, J. Martin, J. Fernandez, C. Almarcegui, J. Ara, and C. Egea Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis Mult Scler. 14 2008 609 614
14. E. Gordon-Lipkin, B. Chodkowski, D.S. Reich, S.A. Smith, M. Pulicken, and L.J. Balcer Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis Neurology. 69 2007 1603 1609
15. J. Sepulcre, M. Murie-Fernandez, A. Salinas-Alaman, A. Garcia-Layana, B. Bejarano, and P. Villoslada Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS Neurology. 68 2007 1488 1494
16. R.C. Sergott Optical coherence tomography: measuring in-vivo axonal survival and neuroprotection in multiple sclerosis and optic neuritis Curr Opin Ophthalmol. 16 2005 346 350
17. M.S. Zaveri, A. Conger, A. Salter, T.C. Frohman, S.L. Galetta, and C.E. Markowitz Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis Arch Neurol. 65 2008 924 928
18. R.C. Sergott, E. Frohman, R. Glanzman, and A. Al-Sabbagh The role of optical coherence tomography in multiple sclerosis: expert panel consensus J. Neurol. Sci. 263 2007 3 14 (Pubitemid 350029827)
19. S.A. Trip, P.G. Schlottmann, S.J. Jones, D.R. Altmann, D.F. Garway-Heath, and A.J. Thompson Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis Ann. Neurol. 58 2005 383 391
20. R.N. Weinreb, S. Shakiba, and L. Zangwill Scanning laser polarimetry to measure the nerve fiber layer of normal and glaucomatous eyes Am J Ophthalmol. 119 1995 627 636
21. L. Frisen, and W.F. Hoyt Insidious atrophy of retinal nerve fibers in multiple sclerosis. Funduscopic identification in patients with and without visual complaints Arch Ophthalmol. 92 1974 91 97
22. F. Honrubia, and B. Calonge Evaluation of the nerve fiber layer and peripapillary atrophy in ocular hypertension Int Ophthalmol. 13 1989 57 62
23. H.A. Quigley, and E.M. Addicks Quantitative studies of retinal nerve fiber layer defects Arch Ophthalmol. 100 1982 807 814
24. G.J. Jaffe, and J. Caprioli Optical coherence tomography to detect and manage retinal disease and glaucoma Am J Ophthalmol. 137 2004 156 169 (Pubitemid 38045202)
25. L.A. Paunescu, J.S. Schuman, L.L. Price, P.C. Stark, S. Beaton, and H. Ishikawa Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using Stratus OCT Invest Ophthalmol Vis Sci. 45 2004 1716 1724
26. F. Costello, S. Coupland, W. Hodge, G.R. Lorello, J. Koroluk, and Y.I. Pan Quantifying axonal loss after optic neuritis with optical coherence tomography Ann Neurol. 59 2006 963 969
27. S. Noval, I. Contreras, G. Rebolleda, and F.J. Muñoz-Negrete Optical coherence tomography versus automated perimetry for follow-up of optic neuritis Acta Ophthalmol Scand. 84 2006 790 794
28. C. Kupfer Retinal ganglion cell degeneration following chiasmal lesions in man Arch Ophthalmol. 70 1963 256 260
29. J. Toledo, J. Sepulcre, A. Salinas-Alaman, A. Garcia-Layana, M. Murie-Fernandez, and B. Bejarano Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis Mult Scler. 14 2008 906 912
30. R.S. Parikh, S.R. Parikh, G.C. Sekhar, S. Prabakaran, J.G. Babu, and R. Thomas Normal age-related decay of retinal nerve fiber layer thickness Ophthalmology. 114 2007 921 926
31. K.J. Smith, R. Kapoor, S.M. Hall, and M. Davies Electrically active axons degenerate when exposed to nitric oxide Ann Neurol. 49 2001 470 476
32. C.F. Brosnan, L. Battistini, C.S. Raine, D.W. Dickson, A. Casadevall, and S.C. Lee Reactive nitrogen intermediates in human neuropathology: an overview Dev Neurosci. 16 1994 152 161
33. J. Imitola, T. Chitnis, and S.J. Khoury Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies Arch Neurol. 63 2006 25 33